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Norepinephrine and dopamine are the common vasopressor
agents used in patients in septic shock who do not respond
to fluid resuscitation. Norepinephrine is a potent
α1-adrenergic agonist with a weaker but still significant
β-adrenergic agonist effect. It increases blood pressure
mainly by increasing systemic vascular resistance as a
consequence of its vasoconstrictive effects. Dopamine has
agonistic effect on a variety of different receptors, depending
on the dose used. At doses below 5 µg/kg per min it acts
predominantly on dopamine receptors (mainly the vascular
D1 receptor); at doses between 5 and 10 µg/kg per min its
β-adrenergic agonist effects are dominant; whereas at doses
above 10 µg/kg per min its α1-adrenergic agonist action
predominates. The American College of Critical Care
Medicine and the Society of Critical Care Medicine in 1999
published practice parameters for the hemodynamic
management of patients in septic shock [1]; despite 197
listed and ranked references, less than a handful of reports
could be categorized as large, prospective, and comparative
in determining the best vasopressor with which to raise
arterial pressure.
Traditionally, the use of norepinephrine in patients with shock
has been restricted by the fear of excessive vasoconstriction
that may result in end-organ hypoperfusion. In the past it was
usually given only when other vasopressor agents failed, and
thus such patients would be predicted to have a poor
outcome. Recent studies indicate that the fear of deleterious
effect was unwarranted and that norepinephrine may have a
role as a first-line vasopressor agent in patients with septic
shock. There are a number of reasons to consider using
norepinephrine first.
Norepinephrine produces less tachycardia
Norepinephrine-induced increase in blood pressure occurs
with little change in the heart rate. This is because the weak
β-agonist chronotropic effect of norepinephrine is
counterbalanced by an increased venous capacitance
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Abstract
Vasopressor agents are often used in patients with septic shock when aggressive fluid resuscitation
fails to correct hypotension. Dopamine and norepinephrine are two such vasopressor agents. In the
past, fear of potential excessive vasoconstriction, with resultant end-organ hypoperfusion, restricted
the use of norepinephrine in septic shock, relegating it to a second-line agent. However, recent data
suggest that this relegation is unmerited and that norepinephrine may even be superior to dopamine in
some respects, and should be considered as the preferred first-line agent. In the present commentary
we review the evidence supporting the use of norepinephrine as the agent of choice in the treatment of
septic shock.
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constriction effect on the right heart baroreceptors. In a
recent study conducted by LeDoux and coworkers [2]
involving 10 patients with septic shock, the dose of
norepinephrine was titrated up in stages to achieve a mean
arterial pressure (MAP) of 65 mmHg, 75 mmHg, and finally
85 mmHg. The mean doses of norepinephrine required to
maintain these MAPs were 23, 31 and 47 µg/min,
respectively, whereas the mean heart rates at these doses
were 97, 101 and 105 beats/min, respectively. In contrast,
tachycardia is among the major undesirable effects of
dopamine at doses exceeding 5 µg/kg per min. In a
crossover study that compared dopamine and
norepinephrine [3], heart rate was found to be significantly
higher while patients were on dopamine. The heart rate
decreased from a mean of 100 beats/min to 91 beats/min in
nine patients when dopamine was changed to
norepinephrine, and increased from a mean of 92 beats/min
to 134 beats/min in 10 patients when norepinephrine was
changed to dopamine.
Increased cardiac index
In years past norepinephrine was linked by many to digital
ischemia and decreased cardiac index (CI). Although this is
true if it is used in hypovolemic shock and may occur with
cardiogenic shock, that is not the case with septic shock. In
fact, norepinephrine has been shown to produce some
increase in CI. In the study conducted by LeDoux and
coworkers [2], the increasing doses of epinephrine required
for the three levels of MAP mentioned above resulted in
progressive increase in the CI (mean values 4.7, 5.3, and
5.5 l/min per m2, respectively). Dopamine also increases CI,
primarily due to an increase in stroke volume, but also partly
due to an increase in heart rate.
No deleterious effect on cerebral perfusion
pressure
Catecholamines normally have no effect on cerebral blood
flow, which is at least partly due to their inability to cross the
blood–brain barrier. After severe brain injury, however, the
blood–brain barrier may be locally disrupted and the
autoregulation of cerebral blood flow impaired. In this
situation it is possible that the cerebral vascular response to
catecholamines may be altered. The cerebral effects of
dopamine and norepinephrine were compared in a recent
crossover study conducted in 19 patients with severe head
trauma requiring vasopressor therapy [3]. The cerebral
perfusion pressure was found to be significantly lower for the
same MAP while the patients were on dopamine. The
cerebral perfusion pressure increased from a mean of 66 to
69 mmHg when dopamine was changed to norepinephrine,
and decreased from a mean of 70 to 61 mmHg when
norepinephrine was changed to dopamine.
No effect on the hypothalamic–pituitary axis
Dopamine has long been known to suppress prolactin,
thyroid-stimulating hormone, and luteinizing hormone
secretions in healthy persons. D2 receptors have been
identified in the anterior pituitary and in the hypothalamic
median eminence. The effect of dopamine on anterior
pituitary function in critically ill patients was reviewed by Van
den Berghe and de Zheger [4]. Dopamine has been found to
suppress the circulating concentrations of all anterior
pituitary hormones except for cortisol. These investigators
noted that a similar pattern is seen in some patients during
prolonged critical illness and suggested that endogenous
dopamine may play a role in the endocrine response to
critical illness. They concluded that the major effect of
prolonged dopamine infusion on the endocrine system is
unlikely to be beneficial and may even be harmful to the
metabolic and immunologic homeostasis of the severely ill
patient. Norepinephrine does not have any known deleterious
effects on the hypothalamic–pituitary axis.
More effective and better outcome as
compared with dopamine
There are few comparisons between the different
vasopressor agents. Norepinephrine is more potent than
dopamine and may be more effective at reversing
hypotension in septic shock patients. In open-label trials,
norepinephrine was shown to increase MAP in patients who
remained hypotensive after fluid resuscitation and dopamine
administration. In a randomized, double-blind trial, Martin and
coworkers [5] compared norepinephrine with dopamine in 32
patients with septic shock. Target MAP and CI was achieved
with dopamine in 31% of patients, whereas the same targets
were achieved in 93% of patients with norepinephrine
(P < 0.001). Of 11 patients who did not respond to
dopamine and remained hypotensive and oliguric, 10 were
successfully treated with the addition of norepinephrine. In a
more recent prospective, nonrandomized study by the same
investigators [6], norepinephrine was compared with
dopamine in 97 patients with septic shock. Mortality was
lower in patients on norepinephrine at day 7 (28% versus
40%; P < 0.005), day 28 (55% versus 82%; P < 0.001), and
hospital discharge (62% versus 84%; P < 0.001). Using
stepwise logistic regression analysis, norepinephrine was
found to be the only factor associated with significantly
improved survival (P = 0.03). Despite the drawback of lack of
randomization, this is the first study, to our knowledge, to link
a survival advantage with any vasopressor.
Amelioration of splanchnic hypoperfusion
Studies evaluating the effects of catecholamines on
splanchnic blood flow have produced conflicting results. In a
study conducted by Ruokonen and coworkers involving
patients with septic shock [7], the effect of norepinephrine
on splanchnic blood flow was considered unpredictable,
whereas dopamine caused a consistent and statistically
significant increase in splanchnic blood flow. However,
Maynard and colleagues [8] were unable to show any effect
of dopamine on intramucosal pH, whereas Neviere and
colleagues [9] found that gastric mucosal blood flow was5
decreased and intramucosal pH was unchanged with
dopamine. Meier-Hellman and coworkers [10] concluded
that, provided cardiac output is maintained, treatment with
norepinephrine alone is without negative effects on
splanchnic tissue oxygenation. One study [11] demonstrated
that norepinephrine preserves splanchnic blood flow better
than does dopamine. In that study, 20 patients with septic
shock were randomly assigned to norepinephrine or
dopamine titrated to maintain an MAP above 75 mmHg. The
gastric intramucosal pH increased significantly in patients on
norepinephrine but decreased significantly in those receiving
dopamine (P < 0.001).
Increased glomerular filtration pressure
In patients with hypovolemic shock, norepinephrine can have
severe detrimental effects on renal perfusion. However, in
hyperdynamic septic shock, urine flow is believed to
decrease mainly as a result of lowered renal perfusion
pressure. Norepinephrine has a greater effect on efferent
than on afferent arteriolar resistance, and thus increases
renal perfusion pressure. In fact, studies have shown that the
addition of norepinephrine to patients with septic shock can
significantly increase urine output [12,13].
Decreased serum lactate concentration
Increased blood lactate concentration may reflect anaerobic
metabolism because of hypoperfusion, but it is also a strong
prognostic indicator. In the study conducted by Martin and
coworkers [5], initial lactate levels were found to be elevated
and patients receiving norepinephrine showed a statistically
and clinically significant decrease in levels. In another study
[14] treatment with a combination of norepinephrine and
dobutamine resulted in a significant decrease in lactate levels.
Conclusion
In summary, although there is no high level evidence that
choosing norepinephrine as the vasopressor of choice in
septic shock leads to a better outcome, there is considerable
physiologic support for that choice. Prospective randomized
trials would be needed to establish this.
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